Innovative life science companies are engaging in promising, cutting-edge biomedical research to address significant needs in the healthcare marketplace. Traditional venture capital firms consider many of these efforts too early stage and too risky, yet some of these technologies have the potential to benefit patients and transform how certain diseases are managed. Remeditex was formed to invest in these high quality, novel projects that are judged to have reasonable prospects for commercial success. Our goal is to validate translational research, making it attractive to a more expansive group of investors.